Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both
13 December 2022 - 12:30AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the
“Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced its first analyst coverage since going public in February
2022 with the initial recommendations as “buy” from both Maxim
Group LLC (“Maxim”) and H.C. Wainwright & Co. (“H.C.
Wainwright”) at price targets of $4 and $7, respectively.
Copies of the full analyst report from Maxim and H.C.
Wainwright, respectively, can be obtained upon request directly
from Maxim and H.C. Wainwright.
“We are thrilled to receive these recommendations from such
esteemed analysts and truly believe that both reports echo our
internal beliefs about our groundbreaking technology,” said Joseph
Hernandez, Chairman and Chief Executive Officer of Blue Water
Vaccines. “While we feel that we are undervalued in the current
market, we believe these reports highlight our transformative
vaccine programs to current and potential investors and will
hopefully show the true value in our mission as we advance our
programs towards clinical trials.”
Disclaimers
The research analysts primarily responsible for the preparation
of the Maxim and the H.C. Wainwright research reports have received
compensation based upon various factors, including the respective
firm’s total revenues, a portion of which is generated by
investment banking activities. Maxim makes a market in Blue
Water Vaccines. Each of Maxim and HC Wainwright have received
compensation for non-investment banking securities-related services
from Blue Water Vaccines in the past 12 months and may provide
investment banking services in the future. HC Wainwright has
previously received compensation for investment banking services in
the last 12 months but does currently not make a market in Blue
Water Vaccines.
Although BWV has paid the above compensation to the analysts,
BWV is not responsible for the content, accuracy or timelines
contained in an analyst’s report and the fee was not dependent on
the opinion provided.
All reports on BWV prepared by analysts represent the views of
such analysts and are not necessarily those of BWV. BWV is not
responsible for the content, accuracy or timelines provided by
analysts. BWV does not expressly or by implication warrant or
assume any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, assumption, data,
forecast, price target, estimate or projection contained in the
reports or industry notes provided by analysts, and the
dissemination of such reports or industry notes does not
necessarily constitute or imply BWV’s endorsement or
recommendation.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children’s Hospital Medical
Center, St. Jude Children’s Hospital, and The University of Texas
Health San Antonio. The Company is developing a universal flu
vaccine that will provide protection from all virulent strains in
addition to licensing a novel norovirus (NoV) S&P nanoparticle
versatile virus-like particle (VLP) vaccine platform from
Cincinnati Children’s to develop vaccines for multiple infectious
diseases, including norovirus/rotavirus and malaria, among others.
Additionally, Blue Water Vaccines is developing a Streptococcus
pneumoniae (pneumococcus) vaccine candidate, designed to
specifically prevent the highly infectious middle ear infections,
known as Acute Otitis Media (AOM), in children, and prevention of
pneumonia in older people at risk for contracting pneumococcal
pneumonia, a significant unmet medical need. The advantage of this
technology includes a serotype independent mucosal immunity that
prevents colonization in the upper respiratory tract as well as
systemic immunity that can confer serotype independent against
invasive pneumococcal disease The Company is also developing a
Chlamydia vaccine candidate with UT Health San Antonio to prevent
infection and reduce the need for antibiotic treatment associated
with contracting Chlamydia disease. For more information, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s
Registration Statement on Form S-1, filed with the Securities and
Exchange Commission (the “SEC”) on August 29, 2022 and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Media Contact Information:Blue Water Media RelationsTelephone:
(646) 942-5591Email: Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024